25 Nov

Change of Directors Interest Notice

Appendix 3Y Change of Directo r’s Interest Notic e + See chapter 19 f o r d efined terms. 01/01/20 11 Appendix 3Y Page 1 Rule 3.19A.2 Appendix 3Y Change of Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/ 0 9/01 Amended 01/01/11 Name of entity Medical Developments International Limited ABN 14 106 340 667 We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the direc tor for the purposes of section 205G of the Corporations Act. Name of Director Christin e Emmanuel - Donnelly Date of last notice 26 Ma y 202 0 Part 1 - Change of director’s relevant interests in securities In the case of a trust, this includes interests in th e t r u st made available by the responsible entity of the trust Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part. Direct or indirect int erest Ind i rec t Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the re l evant interest. John Charles Donnelly & Christine Anna Mari e Emmanuel - Donnelly as T rustee for Donnelly Superannuati on Fund Date of change 25 November 20 21 No. of securities held prior to change Nil Class Fully P a i d Or dinary Shares Number acquired 15 , 38 5 Number disposed Nil Value/Consideration Note: If c o nsidera tion is non - cash, provide details and estimated val uation 1 5,385 shares @ $ 6 . 5 0 per share No. of securiti es he l d after change 15,385 Appendix 3Y Change of Direc tor’s Interest Notice + S ee chapter 19 for defined te rms. Appendix 3Y P age 2 01/01/20 11 Nature of chan ge Examp le: on - market trade, off - market trade, exercise of options, issue of securi ties under d ividend reinvestment plan, participation in buy - back Purch ase of 15 ,385 shares via participation in share placement announc e d on 14 December 20 20 and approved by shareholders at the 2 021 MVP AGM . Part 2 – C hange of director’s interests in c ontra cts Note: In the case of a company, interests wh ich come wi thin p aragraph (ii) of the definition of “n otifiable interest of a dire c tor” should be disclosed in this par t . Detail of contract Not applicable Nature of intere st Name of registered hol der ( if issued securities) Date of change No. and cl ass of s ecurit ies to wh ich interest related prior t o change Note: Det a ils are o n ly required for a contract in relati o n t o which the interest has changed Interest acquir ed Interest disposed Val ue/Co nsideration Note: If consideration is non - cash, p rov ide deta ils an d an esti mated valuation Interest after change P a rt 3 – + C l osed period Were the interests in t h e s ecurities or contracts detailed above traded during a + closed period where prio r wri tten clearance was required? No If so, was prio r wr itten cl earanc e provide d to allow the trade to proc eed during this pe r iod? N/A If prior written clearance was prov i ded , on what date was this provided? N/A
Information on this Website is provided for general information purposes only and is not a substitute for professional advice. ASX Information (including company announcements and prices) is delayed by at least 20 minutes. JSE Information (including company announcements and prices) is delayed by at least 15 minutes. Reliance on the information you access on or from this Website is solely at your own risk. We make no representation or warranty in relation to the future performance of the companies that appear on this Website. Investment in securities involves risk and you should obtain independent professional legal, financial, investment or company advice before acting on any of the information you access on this Website. Using, browsing or otherwise accessing this Website is subject to our Terms and Conditions and our Privacy Policy.

© 2021 Listcorp. ABN 60 166 140 307

Never miss news from Medical Developments International (ASX:MVP) when you join Listcorp.